xi3A11 antibody drug conjugate (Leidos Biomedical Research/NCI)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug Namexi3A11 antibody drug conjugate (Leidos Biomedical Research/NCI)
Drug Alias NameAnti-FGFR4 Antibody Drug Conjugate (Leidos/NCI)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionFibroblast growth factor receptor 4 antagonists
TargetsFibroblast growth factor receptor 4
Therapy Area/IndicationsCarcinoma, HepatocellularRhabdomyosarcoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesLeidos Biomedical Research Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesLeidos Biomedical Research IncNational Cancer Institute
Active IndicationsN/A
Inactive IndicationsCarcinoma, HepatocellularRhabdomyosarcoma

Other Information

ATC CodeN/A
Related LinksN/A